Uh, you see this photograph? I think there is nobody in this hall who must not have had a relative or somebody he knows who has not suffered from obesity. The problem of being overweight either some of your relatives would have suffered it or you yourself would have. And the problem with obesity is that there is just not the weight of the body there is also that weight of the shame. But guess this is the surprise. I never wanted to treat obesity in my life. Never. In fact, all I wanted to be is to become th ...

Core Insights - Intuitive Surgical is a leader in robotic surgery equipment with over 9,900 da Vinci systems installed globally, used in more than 16 million procedures [1] - Approximately 25% of Intuitive Surgical's revenue comes from system sales, while the remaining 75% is generated from servicing and supplies, providing a stable revenue stream [2] - The company's stock is highly valued, with a forward P/E ratio of 59, slightly above its five-year average of 56, reflecting its status as a strong growth stock [3] Company Comparisons - Medtronic is making strides in robotic surgery and offers a more attractive valuation with a forward P/E of 18, just above its five-year average of 17 [4] - Medtronic has focused on higher-margin operations and divested its less profitable diabetes division, maintaining a solid dividend yield of 2.8% [5] - Medtronic's recent earnings report indicated robust procedure volumes and market performance, with revenue and EPS exceeding expectations [5]

Distalmotion has closed a Series G funding round totalling $150m to expedite the expansion of its soft tissue robotic surgery system, DEXTER, in the US. The funds will also be directed to support product and clinical development efforts that are currently underway. The round was spearheaded by Revival Healthcare Capital, with participation from inside investors. A central aspect of Distalmotion’s strategy is to target the Ambulatory Surgery Center (ASC) segment in the US. DEXTER has already been in cli ...

Core Insights - The recent market correction has created buying opportunities for investors in high-growth companies that are addressing real-world problems, with many stocks trading at 30-day lows despite strong operational progress [1][2]. Group 1: Symbotic (SYM) - Symbotic develops AI-enabled robotic systems for automating high-volume warehouses, reporting Q3 2025 revenue of $592 million, a 26% year-over-year increase, and adjusted EBITDA rising to $45 million from $3 million [3][5]. - The company has a significant backlog of approximately $22.4 billion, primarily from long-term contracts with Walmart and GreenBox, providing multiyear revenue visibility [5][6]. - Despite a 14% decline in shares over the past 30 days, the company is positioned for growth with a substantial contracted workload ahead [6]. Group 2: AST SpaceMobile (ASTS) - AST SpaceMobile aims to create the first space-based cellular broadband network compatible with standard smartphones, achieving Q3 2025 revenue of $14.7 million, up from $1.1 million a year ago, driven by government contracts [7][9]. - The company has over $1 billion in contracted revenue commitments and has signed agreements with more than 50 mobile network operators, serving nearly 3 billion subscribers [9][10]. - Execution and launch timelines are critical factors, with recent revenue misses contributing to stock volatility, but the current weakness offers a favorable entry point for investors [10]. Group 3: SS Innovations International (SSII) - SS Innovations has installed over 100 SSi Mantra surgical robotic systems and completed over 5,000 procedures, indicating a transition from concept to scale [11][13]. - The company plans to file a 510(k) premarket notification in Q4 2025 for multiple surgical indications, which could expedite FDA clearance [13][14]. - This small-cap stock has shown less volatility compared to others, with only a 5% decline over the past 30 days as investors await regulatory updates [15].

Core Insights - SS Innovations has successfully completed the first telesurgery using its SSi Mantra Tele Surgeon Console (TSC), marking a historic milestone in robotic telesurgery [1][4][5] Group 1: Product Overview - The SSi Mantra Tele Surgeon Console is a compact, self-contained, chair-based system designed for telesurgery, allowing operations from various locations, including physician offices [2][4] - The TSC features 3D visualization, magnetic sensor controls, and a smaller footprint compared to traditional operating room setups, enhancing flexibility for surgical experts [7][9] Group 2: Surgical Achievement - Dr. Sudhir Srivastava performed a robotic-assisted coronary artery bypass surgery remotely from New Delhi on a patient located 185 miles away in Jaipur, demonstrating the TSC's capability to extend surgical expertise globally [3][5] Group 3: Company Vision and Future Plans - SS Innovations aims to make robotic surgery affordable and accessible to a broader global population, with plans to expand its presence and technological offerings [8] - The company has refined the TSC since its initial showcase at the Society of Robotic Surgery Meeting in June 2024, indicating ongoing innovation and development [5]

Core Insights - SS Innovations International, Inc. has successfully completed its first telesurgery using the SSi Mantra Tele Surgeon Console (TSC), demonstrating the console's capability to facilitate surgeries from various locations, including physician offices [1][2][3] Company Overview - SS Innovations is focused on developing innovative surgical robotic technologies aimed at making robotic surgery affordable and accessible globally [4] - The company is headquartered in India and plans to expand its global presence with user-friendly and cost-effective surgical robotic solutions [4] Product Details - The SSi Mantra Tele Surgeon Console is a compact, self-contained chair-based system that allows for telesurgeries without the need for a full operating room [1][3] - The TSC features inbuilt electronics, lightweight glasses, a magnified 3D view, and magnetic sensor-based controls, making it suitable for remote surgical procedures [3] - The SSi Mantra surgical robotic system includes modular robotic arms, a 3D 4K monitor, and supports over 40 types of robotic endo-surgical instruments for various specialties, including cardiac surgery [5]

Core Insights - Intuitive Surgical (ISRG) reported strong third-quarter 2025 performance, with adjusted earnings per share of $2.40, exceeding the consensus estimate of $1.99, and revenues increased by 23% year over year to $2.51 billion, driven by robust procedure growth and higher system placements [1][11] Group 1: Performance Metrics - Worldwide procedure volumes rose by 20%, with da Vinci procedures increasing by 19% and Ion lung biopsy procedures soaring by 52% [2] - The installed base of da Vinci systems grew by 13% to nearly 10,800, with over 900 da Vinci 5 systems now in operation [2] Group 2: Growth Drivers - The da Vinci 5 upgrade cycle has stimulated demand and utilization, with nearly 90% of da Vinci 5 procedures utilizing integrated technologies [3] - International markets contributed to a 25% growth in procedures, supported by placements in Japan, Europe, and emerging markets [2] Group 3: Challenges and Competition - Management noted ongoing declines in bariatric surgery volumes due to GLP-1 adoption and competitive pressures in China [4] - Johnson & Johnson (JNJ) is intensifying its focus on robotic surgery with its OTTAVA system, planning to file for FDA submission in early 2026 [6][7] - Stereotaxis is advancing its GenesisX robotic surgery platform, with CE Mark approval secured and initial hospital installations planned for 2025 [8][9] Group 4: Financial Outlook - Gross margin decreased by 90 basis points year over year to 68%, influenced by tariffs, product mix, and higher facility costs [4] - The Zacks Consensus Estimate for Intuitive Surgical's 2025 earnings suggests a 17.3% increase from the previous year [14] - Intuitive Surgical's stock has gained 5.6% year-to-date, outperforming the industry [12]

Core Insights - Intuitive Surgical (NASDAQ: ISRG) is the leading player in the robotic surgery market, primarily due to its first-mover advantage with the da Vinci surgical system [1] Company Overview - The da Vinci system has become the standard training tool for surgeons who utilize robotic machinery, indicating its dominance in the market [1] Market Position - Intuitive Surgical's early entry into the robotic surgery field has established a significant competitive edge, making it the preferred choice for surgical training [1]

Core Insights - Intuitive Surgical reported third-quarter revenue of $2.51 billion, a 23% year-over-year increase, surpassing analyst expectations of $2.40 billion [1] - The company achieved adjusted earnings of $2.40 per share, exceeding analyst estimates of $1.98 [2] - The growth in revenue was attributed to an increase in procedure volume, higher placements of da Vinci systems, and a larger installed base of systems [2] Revenue and Earnings Performance - Worldwide da Vinci procedures grew by approximately 20% year-over-year [3] - The company placed 427 da Vinci surgical systems in the quarter, compared to 379 in the same quarter last year [3] - The installed base of da Vinci surgical systems reached 10,763, reflecting a 13% year-over-year growth, while the Ion endoluminal system installed base grew by 30% to 954 systems [4] Market Sentiment and Analyst Commentary - The strong quarterly results alleviated some bearish concerns regarding capital expenditure budgets and margin pressures [4] - Analysts view the minor headwinds as largely inconsequential, affirming Intuitive Surgical's position in the market transitioning to robotics [5] - The stock is currently trading at 47 times the expected earnings per share for 2026, with an Outperform rating maintained by analysts [5] Future Guidance - Intuitive Surgical anticipates a 17% to 17.5% increase in worldwide da Vinci procedures for the full year 2025, up from previous guidance of 15.5% to 17% [6] - The expected gross profit margin for 2025 is projected to be between 67% and 67.5% of revenue, down from 69.1% in 2024 [6] - The company introduced new software capabilities for its da Vinci 5 surgical system aimed at enhancing surgeon performance and hospital efficiency [6] Stock Performance - Intuitive Surgical's stock price increased by 14.62%, reaching $530.21 at the time of publication [7]

Core Insights - Intuitive Surgical's new robotic surgery system, da Vinci 5, is gaining traction, contributing to significant stock price increases and strong earnings reports [1][3][4] Financial Performance - Intuitive Surgical reported third-quarter sales of $2.51 billion, a 23% increase year-over-year, surpassing expectations of $2.41 billion [6] - The company achieved an adjusted earnings per share of $2.40, exceeding analysts' forecasts of $1.99 [6] - Instrument and accessory sales reached $1.52 billion, growing 20% due to strong procedure growth [5] Procedure Growth - Worldwide procedure growth was reported at 20%, with da Vinci systems contributing 19% and Ion systems, which perform lung biopsies, contributing 52% [4] - The company now expects procedure growth for the year to be between 17% and 17.5%, compared to last year's growth of 17% [5] - Analysts had initially projected a lower procedure growth of 15.8% [5] Da Vinci System Installations - In the third quarter, Intuitive Surgical installed 427 new da Vinci systems, including 240 of the da Vinci 5, compared to 379 and 110 installations in the same period last year [7] - The company also placed 50 Ion systems, a slight decrease from 58 in the previous year [7] Market Sentiment - Analysts maintain a positive outlook on Intuitive Surgical, with some noting potential concerns regarding procedure pull-forward in the U.S. and international capital expenditure weaknesses [8] - Overall, the third-quarter results are viewed as a strong endorsement of durable growth trends in the robotic surgery market [9]